Almirall SA (ALM):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Almirall SA (ALM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C10035)・商品コード:DATA904C10035
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:69
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Almirall SA (Almirall) is a specialty pharmaceutical company which researches, develops, manufactures and commercializes proprietary medicines and licensed products. The company’s key area of focus is dermatology covering psoriasis, eczema, acne and other skin infections. It also develops products in the autoimmune diseases including rheumatoid arthritis and multiple sclerosis; and gastrointestinal diseases including irritable bowel syndrome with constipation. Some of its major products include Actikerall, Balneum; Solaraze; Decoderm and Sativex among others. The company also works together with small and medium sized companies for the development of drugs and their marketing. It operates through affiliates in Europe and Central America and has R&D centers in Spain and Germany. Almirall is headquartered in Barcelona, Spain.

Almirall SA (ALM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Almirall SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Almirall SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Almirall SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Almirall SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Almirall SA, Medical Devices Deals, 2012 to YTD 2018 12
Almirall SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Almirall SA, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Almirall Acquires Dermatology Portfolio from Allergan 15
Almirall Acquires Rights to Veltin and Altabax from Stiefel 16
Aqua Pharma Acquires US Rights To Verdeso Foam From Stiefel 17
Partnerships 18
Evotec and Almirall Enter into Research Agreement 18
Almirall Enters into Research Agreement with Mercachem 19
Nuevolution Enters into Co-Development Agreement with Almirall 20
Medigene Enters Into Co-Marketing Agreement With Taurus Pharma For Veregen 21
Almirall Enters Into Commercialization Agreement With Quintiles 22
Bayer HealthCare And Almirall Enter Into Co-Promotion Agreement For Rivaroxaban In Spain 23
Almirall Enters Into Integrated Drug Discovery Collaboration With BioFocus 24
Licensing Agreements 25
Almirall Enters into Licensing Agreement with AstraZeneca 25
Almirall Signs Licensing Agreement with Athenex for KX2-391 26
Luqa Pharma Enters into Licensing Agreement with Polichem 27
Almirall Enters into Licensing Agreement with Patagonia Pharma 28
Almirall Enters into Licensing Agreement with Bicosome 29
Allergan Enters into Licensing Agreement with Almirall for Constella 30
Aslan Pharma Expands Licensing Agreement with Almirall for LAS186323 31
Almirall Enters into Licensing Agreement with Sun Pharma for Tildrakizumab 32
Laboratorios Rubio Enters Into Licensing Agreement With Polichem 33
Almirall Enters Into Licensing Agreement With Forest Labs For Aclidinium bromide 34
Almirall Enters Into Licensing Agreement With Invida For Aclidinium 35
Almirall Enters Into Licensing Agreement With Forest Labs For Linaclotide 37
Almirall Enters Into Licensing Agreement With Menarini Biotech For Aclidinium Bromide 38
Almirall Enters Into Licensing Agreement With Daewoong Pharma For Aclidinium 39
Equity Offering 40
Suneva Medical Raises USD15 Million in Series C Equity Investment 40
Debt Offering 41
Almirall Raises USD447.4 Million in Private Placement of 4.625% Notes Due 2021 41
Asset Transactions 42
Cipher Pharma Acquires Canadian Rights to Vaniqa and Actikerall from Almirall 42
Astrazeneca Acquires Almirall Respiratory Franchise for up to USD2.1 billion 43
Acquisition 45
Grunenthal Group to Acquire Almirall de Mexico for USD33.4 Million 45
Almirall Acquires Poli 46
Actavis May Acquire Almirall 47
Almirall Completes Acquisition Of Aqua Pharma From RoundTable Healthcare Partners For US$403 Million 48
Almirall Acquires Stake In AB-Biotics, Biotechnology Company, For US$1.3 Million 50
Almirall SA – Key Competitors 51
Almirall SA – Key Employees 52
Almirall SA – Locations And Subsidiaries 53
Head Office 53
Other Locations & Subsidiaries 53
Recent Developments 55
Strategy And Business Planning 55
Aug 06, 2018: Allergan divests five dermatology medicines to Almirall for $550m 55
Sep 13, 2017: Almirall Renews its Corporate Identity, Aligned with its Focus on Skin Health 56
Financial Announcements 57
May 14, 2018: Almirall Announces Financial Results Q1 2018 57
Feb 23, 2018: Almirall’s Full-Year 2017 Results 59
Nov 06, 2017: Almirall’s Q3 results 2017 61
Jul 24, 2017: Almirall’s H1 Results 2017: Reiterating Recent Guidance 63
May 08, 2017: Almirall’s Q1 results 2017, driven by Dermatology in Europe 64
Feb 27, 2017: Almirall Full-Year 2016 results: Strong Dermatology results and promising pipeline 66
Corporate Communications 68
Aug 22, 2017: Almirall announces Ron Menezes as new President & General Manager at Aqua Pharmaceuticals 68
Appendix 69
Methodology 69
About GlobalData 69
Contact Us 69
Disclaimer 69

List of Tables
Almirall SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Almirall SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Almirall SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Almirall SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Almirall SA, Deals By Therapy Area, 2012 to YTD 2018 10
Almirall SA, Medical Devices Deals, 2012 to YTD 2018 12
Almirall SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Almirall Acquires Dermatology Portfolio from Allergan 15
Almirall Acquires Rights to Veltin and Altabax from Stiefel 16
Aqua Pharma Acquires US Rights To Verdeso Foam From Stiefel 17
Evotec and Almirall Enter into Research Agreement 18
Almirall Enters into Research Agreement with Mercachem 19
Nuevolution Enters into Co-Development Agreement with Almirall 20
Medigene Enters Into Co-Marketing Agreement With Taurus Pharma For Veregen 21
Almirall Enters Into Commercialization Agreement With Quintiles 22
Bayer HealthCare And Almirall Enter Into Co-Promotion Agreement For Rivaroxaban In Spain 23
Almirall Enters Into Integrated Drug Discovery Collaboration With BioFocus 24
Almirall Enters into Licensing Agreement with AstraZeneca 25
Almirall Signs Licensing Agreement with Athenex for KX2-391 26
Luqa Pharma Enters into Licensing Agreement with Polichem 27
Almirall Enters into Licensing Agreement with Patagonia Pharma 28
Almirall Enters into Licensing Agreement with Bicosome 29
Allergan Enters into Licensing Agreement with Almirall for Constella 30
Aslan Pharma Expands Licensing Agreement with Almirall for LAS186323 31
Almirall Enters into Licensing Agreement with Sun Pharma for Tildrakizumab 32
Laboratorios Rubio Enters Into Licensing Agreement With Polichem 33
Almirall Enters Into Licensing Agreement With Forest Labs For Aclidinium bromide 34
Almirall Enters Into Licensing Agreement With Invida For Aclidinium 35
Almirall Enters Into Licensing Agreement With Forest Labs For Linaclotide 37
Almirall Enters Into Licensing Agreement With Menarini Biotech For Aclidinium Bromide 38
Almirall Enters Into Licensing Agreement With Daewoong Pharma For Aclidinium 39
Suneva Medical Raises USD15 Million in Series C Equity Investment 40
Almirall Raises USD447.4 Million in Private Placement of 4.625% Notes Due 2021 41
Cipher Pharma Acquires Canadian Rights to Vaniqa and Actikerall from Almirall 42
Astrazeneca Acquires Almirall Respiratory Franchise for up to USD2.1 billion 43
Grunenthal Group to Acquire Almirall de Mexico for USD33.4 Million 45
Almirall Acquires Poli 46
Actavis May Acquire Almirall 47
Almirall Completes Acquisition Of Aqua Pharma From RoundTable Healthcare Partners For US$403 Million 48
Almirall Acquires Stake In AB-Biotics, Biotechnology Company, For US$1.3 Million 50
Almirall SA, Key Competitors 51
Almirall SA, Key Employees 52
Almirall SA, Subsidiaries 53

List of Figures
Almirall SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Almirall SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Almirall SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Almirall SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Almirall SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Almirall SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Almirall SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Almirall SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Almirall SA, Medical Devices Deals, 2012 to YTD 2018 12

★調査レポート[Almirall SA (ALM):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C10035)販売に関する免責事項を必ずご確認ください。
★調査レポート[Almirall SA (ALM):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆